For the second consecutive year, the rapid expansion of Medicare Advantage has stalled, with federal projections pointing to an enrollment decline in 2026 and major insurers pulling back from markets they once aggressively pursued. The slowdown signals a structural shift in the program that covers tens of millions of older Americans through private health plans, driven by rising medical costs, tighter federal payment rules, and insurer losses that are forcing difficult choices about where and how to compete. What was once a reliable growth engine for the insurance industry is now a source of financial strain, and the consequences are beginning to reach beneficiaries directly.
Enrollment Projections Point Downward for 2026
The clearest sign of the stall comes from the federal government itself. In a September 2025 release, the Centers for Medicare & Medicaid Services (CMS) projected that overall Medicare Advantage participation will edge down in 2026, a marked departure from the double-digit annual growth rates the program enjoyed for much of the past decade. The agency described the outlook as “stable,” but stability is a generous reading when the trajectory has shifted from steady expansion to the first signs of contraction, especially given the program’s central role in covering older adults.
The numbers tell a consistent story of modest retreat. The national count of available Medicare Advantage plans is projected to drop from 5,633 in 2025 to approximately 5,600 offerings in 2026, a small reduction in raw terms but one that reflects a broader pattern of insurers trimming their portfolios rather than expanding them. Average monthly premiums are projected to fall from $16.40 in 2025 to $14.00 in 2026, which sounds like good news for enrollees but in practice reflects plan redesigns and cost shifting meant to attract or retain members amid growing competitive pressure and tighter margins.
Insurers Retreat From Key Markets
Behind the aggregate numbers, individual insurance companies are making concrete decisions to scale down their Medicare Advantage footprints. CVS Health Corp. and Humana Inc. are among the major players reducing plan participation heading into 2026, including cutting back Medicare prescription drug offerings in multiple states. These are not marginal participants; they rank among the largest Medicare Advantage carriers in the country, and their pullbacks affect hundreds of thousands of beneficiaries who may need to find new coverage or switch back to traditional Medicare during the annual enrollment period.
The financial pressure driving these decisions is visible in corporate earnings reports and forward-looking guidance. Humana reported a wider quarterly loss tied to surging medical costs and signaled that its 2026 earnings are likely to decline further, underscoring the strain that elevated utilization is placing on the Medicare Advantage business line. When one of the program’s dominant carriers is losing money on its core product and warning investors of more pain ahead, the broader market signal is hard to ignore. Rising use of outpatient procedures, behavioral health services, and specialty drugs has pushed medical cost ratios well above the levels insurers assumed when they submitted their bids, leaving little room to absorb additional shocks.
Access Holds Steady, but the Mix Is Changing
CMS has emphasized that access to Medicare Advantage remains broadly intact despite the slowdown. According to the agency’s September 2025 projections, more than 99% of Medicare beneficiaries will continue to have at least one private plan available in 2026, a statistic meant to reassure seniors that the program remains robust. That headline figure, however, masks important geographic variation: a beneficiary in a dense urban market may still see dozens of choices, while someone in a rural county may have only one or two remaining options, and those plans may feature higher cost-sharing or narrower provider networks than what was available a year earlier.
The distinction between nominal access and the quality of access matters enormously for the seniors who rely on these plans. Beneficiaries can still compare available options using the federal online plan finder, but the menu of choices itself is shifting as insurers exit certain counties or consolidate overlapping products. Fewer competitors in a given market can translate into reduced supplemental benefits (such as dental, vision, and hearing coverage) that have long been a major selling point for Medicare Advantage over traditional fee-for-service Medicare. The program’s value proposition has always rested on offering more for less, and that equation is getting harder for insurers to sustain without cutting back somewhere.
Rising Medical Costs Squeeze Plan Economics
The fundamental problem is a growing mismatch between what insurers are paid and what care actually costs. Medicare Advantage plans receive a fixed per-member payment from the federal government, adjusted for the health status of their enrollees through a risk-scoring system. When medical utilization rises faster than those payments, insurers absorb the difference, and that is exactly what has been happening. Post-pandemic utilization patterns have not reverted to pre-2020 baselines: seniors are seeking more elective surgeries, more intensive management of chronic conditions, and more mental health and substance use services than actuarial models predicted, all against the backdrop of broader healthcare inflation.
This cost pressure was already evident when CMS laid out its 2025 outlook, describing the program as stable while highlighting that plan bids and benefits reflected tighter economics. The 2026 projections confirm that the strain has deepened rather than eased. Insurers that once competed aggressively on price and extras to grab market share are now focused on protecting margins, which means exiting unprofitable counties, trimming supplemental benefits like gym memberships and over-the-counter allowances, and tightening provider networks to steer patients toward lower-cost settings of care.
Federal Payment Rules Add Pressure for 2027
Looking ahead, the regulatory environment is unlikely to offer insurers much relief. On January 26, 2026, CMS unveiled proposed payment updates for 2027 for both Medicare Advantage and Part D drug coverage, explicitly framed around improving “payment accuracy” and ensuring long-term sustainability. In practice, efforts to tighten accuracy often mean reducing overpayments that have historically flowed to plans through aggressive diagnostic coding and favorable benchmarks, a longstanding concern for policymakers who argue that private plans should not be paid more than what the same beneficiaries would cost in traditional Medicare.
The proposed 2027 rules could accelerate the market consolidation that is already underway. Smaller regional plans with thin capital reserves may find it impossible to absorb both elevated utilization and any downward pressure on federal payments at the same time, particularly if they lack the negotiating leverage with hospitals and physician groups that national carriers possess. CMS makes available detailed monthly enrollment files at the state, county, and contract level, and tracking those data over the next two years will reveal whether exits and consolidations are concentrated in specific regions (such as rural areas or high-cost states) or spread more broadly across the map.
A Market Correction, Not a Collapse
Industry leaders and federal officials have largely framed the current moment as a period of stabilization rather than crisis, emphasizing that most beneficiaries will still have multiple options and that average premiums remain low. That framing deserves some skepticism. Two consecutive years of slowing or declining enrollment, combined with insurer exits and widening losses at major carriers, look more like a market correction than a temporary pause. Medicare Advantage expanded rapidly in part because payment rates and risk-adjustment rules were generous enough to let insurers offer rich benefits at low or zero premiums. As those economics tighten, the program is reverting toward a more sustainable but less lavish equilibrium.
Still, this is not a collapse. More than 99% of beneficiaries retain access to at least one private plan, and Medicare Advantage continues to cover a substantial share of the overall Medicare population. The underlying federal Medicare program remains a guaranteed backstop, with traditional fee-for-service coverage available to anyone who opts out of private plans, and low-income seniors may qualify for additional help with premiums and cost sharing through state-administered Medicaid coverage. For beneficiaries navigating this shifting landscape, the key will be to review plan materials carefully each year, use comparison tools to assess premiums, networks, and benefits, and seek out trusted counseling resources, including state health insurance assistance programs that are listed in federal beneficiary guides. The slowdown in Medicare Advantage growth marks a significant turning point, but it also offers an opportunity to rebalance the program toward long-term fiscal stability while preserving meaningful choice for older Americans.
More From The Daily Overview
*This article was researched with the help of AI, with human editors creating the final content.
Nathaniel Cross focuses on retirement planning, employer benefits, and long-term income security. His writing covers pensions, social programs, investment vehicles, and strategies designed to protect financial independence later in life. At The Daily Overview, Nathaniel provides practical insight to help readers plan with confidence and foresight.
